Clinical trials: Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
- Condition Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
- Has posted results yes
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.
- Trial name
- NCT03938246
- Testing
- TVB-2640 25 mg (US), TVB-2640 50 mg (US), TVB-2640 50 mg (China)
- Where
- 23 sites in United States, China
- Volunteers
- 142 people
- Sponsor
- Sagimet Biosciences Inc.